Recorded Presentation from the NCCN 2018-2019 Oncology Case Manager and Medical Director Program: Management of Bone Health in Patients with Cancer
With the improved effectiveness of cancer treatment, more and more patients are surviving longer and may experience fractures as a long-term complication of bone loss. Much of the morbidity and mortality associated with bone loss and fractures is preventable with appropriate screening followed by lifestyle interventions. In the real world, not all cancer patients at risk for bone loss undergo screening. Effective screening and timely interventions are essential for reducing bone-related morbidity. Education on causative risk factors, mechanisms, and prevention and treatment strategies for cancer therapy-related bone loss in hematologic and specific solid malignancies is important.
The management of long-term bone health for patients with cancer requires a broad knowledge and full understanding of the complementary benefits of available agents along with potential limitations. Although the risk/benefit ratio is usually markedly in favor of treatment, clinicians should be aware of potential adverse effects from these agents used in preventing bone loss, including patient populations deriving benefit, timing, scheduling of therapy, and specific clinical benefits.
This program is designed to meet the educational needs of case managers, nurses in other roles (e.g., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.
Following this activity, participants should be able to:
- Effectively assess patients at risk for cancer-related skeletal complications and select appropriate management strategy.
- Outline current indications, dosing and administration of currently available bone-targeted agents used in patients with cancer.
- Describe the adverse effects and safety considerations of the bone-targeted agents.
Azeez Farooki, MD
Memorial Sloan Kettering Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below disclose the following relevant financial relationships:
Azeez Farooki, MD
Alexion Pharmaceuticals, Inc.: Consulting Fee; Other financial benefit
Amgen Inc.: Consulting Fee; Honoraria; Scientific Advisor
Celgene Corporation: Consulting Fee
Genentech, Inc.: Consulting Fee
IBSA Pharma Inc.: Consulting Fee
Novo Nordisk A/S: Consulting Fee
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until 8/10/2018); Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP (employed by NCCN until 12/3/2018)
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Katherine Pierce (employed by NCCN until 11/16/2018)
Boston Scientific Corporation: Equity Interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.91 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-19-013-H01-P
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00035068; Approval #: 180004754
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 0.91 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing